Digital Therapeutics for ADHD: Apps, Games & Neurofeedback

Digital therapeutics for ADHD are software-based treatments designed to improve specific symptoms like inattention or impulsivity. They range from FDA-cleared prescription games to consumer apps with no published clinical data. The field is growing quickly, but the evidence behind individual products varies enormously, and understanding that gap can help you make better decisions about non-medication options.

What are digital therapeutics?

Digital therapeutics (DTx) are software programs intended to treat or manage a medical condition, delivered through apps, games, or web platforms. Unlike general wellness apps, true DTx are built on clinical evidence and, in some cases, require a prescription. The distinction matters because the term "digital therapeutic" is increasingly used by marketing teams for products that have never been tested in a clinical trial.

The FDA regulates medical device software, including certain mobile applications, based on the function the software performs and the risk it poses to patients (FDA, 2022) [5]. A product that claims to treat ADHD symptoms falls under this oversight. A product that simply helps you set reminders or track habits generally does not.

A 2025 review examining the development of digital therapeutics for neurodevelopmental disorders highlighted several challenges: establishing consistent evidence standards, integrating DTx into existing clinical workflows, and ensuring products remain effective across diverse patient populations (Lee et al., 2025) [3]. These are not solved problems. The field is still working out how to build, test, and deliver these tools reliably.

Evidence tiers for ADHD digital tools

This table is the single most important framework for evaluating any ADHD digital product. When someone recommends a tool, your first question should be: which tier does it belong to?

Is any digital therapeutic FDA-cleared for ADHD?

Yes. AKL-T01, marketed as EndeavorRx, is the only game-based digital therapeutic that has received FDA clearance for ADHD. It is currently authorized for children aged 8 to 12 with a confirmed ADHD diagnosis, delivered as a prescription video game that targets attentional control through adaptive sensory and motor challenges.

The original FDA clearance was based on randomized controlled trial data in children. More recently, two single-arm trials extended testing to older age groups. The STARS-ADHD-Adolescent trial enrolled 162 adolescents (ages 13 to 17) for four weeks, and the STARS-ADHD-Adult trial enrolled 221 adults (age 18 and older) for six weeks. Both groups showed statistically significant improvements on the Test of Variables of Attention (TOVA), with adults showing a mean improvement of 6.5 points on the Attention Comparison Score. Adverse effects were reported by 15 participants, all mild or moderate (Stamatis et al., 2024) [1].

These results are promising but come with a clear limitation: both trials used a single-arm design, meaning there was no control group receiving a placebo or sham treatment. Without a control group, it is difficult to separate the effect of the intervention from the effect of simply doing something engaging for several weeks. The researchers acknowledged this limitation directly.

A 2024 meta-analysis of randomized controlled trials found that game-based DTx improved parent-reported and teacher-reported inattention more than control conditions. But the same analysis found that medication improved inattention significantly more than game-based DTx (Oh et al., 2024) [4]. In practical terms, current game-based DTx appear to offer a modest benefit for inattention, but they are not a replacement for first-line treatments.

"Game-based DTx had a more significant effect than the control, however medication was more effective." Oh et al., 2024 [4]

If you are exploring whether ADHD might be part of your experience, you can take a quick ADHD screening as a first step before discussing treatment options with a clinician.

What does the evidence say about neurofeedback for ADHD?

Neurofeedback sessions typically run 30 to 40 times before measurable attention changes appear in research trials.

Neurofeedback trains a person to modify their own brainwave patterns using real-time EEG feedback, typically displayed on a screen. The idea is that people with ADHD can learn to increase certain brainwave frequencies associated with focus and reduce those associated with mind-wandering. Research on neurofeedback for ADHD spans decades, but results across trials remain inconsistent.

Some studies report improvements in attention and reduced hyperactivity. Others find no significant difference between neurofeedback and sham (placebo) neurofeedback when blinded assessments are used. The 2025 systematic review of 26 reviews on digital interventions for ADHD noted that while some neurofeedback studies showed positive effects, the overall evidence quality was generally low, and adverse effects were inconsistently documented across studies (Gabarron et al., 2025) [2].

Most major clinical guidelines, including those from NICE in the UK, do not currently recommend neurofeedback as a standalone ADHD treatment. Some clinicians offer it as a complement to medication or behavioral strategies, but this use is based on clinical judgment rather than strong guideline support.

Practical considerations for neurofeedback

• Sessions typically run 30 to 60 minutes, two to three times per week, for 20 to 40 sessions total.
• Cost is often substantial (sometimes several thousand dollars for a full course) and is rarely covered by insurance.
• Home-based EEG devices are becoming more available, but the quality of the signal and the training protocols vary widely between products.
• If you are considering neurofeedback, ask the provider which specific protocol they use, what published evidence supports it, and whether they use blinded outcome measures.

Does computerized cognitive training help with ADHD?

Computerized cognitive training programs target specific mental skills, typically working memory, sustained attention, or inhibitory control, through repeated exercises that adapt in difficulty. The theory is that strengthening these foundational skills will improve ADHD symptoms in daily life. The evidence for this transfer from training to real-world improvement is mixed.

Working memory training is the most studied form. Some trials show improvements on the trained tasks themselves, but the question is whether those gains carry over to untrained tasks and everyday functioning. Many reviews have found limited evidence of meaningful transfer. A person may get better at the specific game or exercise without experiencing noticeable changes in their ability to manage work, conversations, or daily routines.

The 2025 umbrella review covering 26 systematic reviews and over 34,000 participants found that computerized cognitive training showed some positive effects on inattention and executive function, but described the evidence as generally low quality (Gabarron et al., 2025) [2]. Adverse effects from cognitive training programs were less commonly reported than from game-based interventions, but the review noted that safety reporting across all digital intervention studies was inconsistent.

For adults exploring non-medication ADHD treatments, cognitive training may have a role as one component of a broader management plan, but it should not be expected to replace established treatments based on current evidence.

What about AI-powered ADHD programs?

AI-driven ADHD programs personalize difficulty in real time, adjusting to each user's attention patterns.

A growing number of companies are developing AI-driven tools that adapt to a user's behavior in real time, adjusting difficulty, content, or coaching prompts based on performance data. Some aim to personalize cognitive training. Others function more like AI-powered coaching apps that send reminders, suggest strategies, or track patterns over time.

The concept is appealing: an intervention that learns your specific patterns and adjusts accordingly could, in theory, be more effective than a one-size-fits-all program. But the published evidence for AI-powered ADHD interventions is still very limited. Most products in this category have not completed randomized controlled trials, and many rely on user satisfaction surveys rather than clinical outcome measures.

Lee et al. (2025) noted that integrating AI and machine learning into digital therapeutics for neurodevelopmental disorders is a promising direction, but highlighted that regulatory frameworks, evidence standards, and real-world deployment challenges remain unresolved (Lee et al., 2025) [3].

Questions to ask about any AI-powered ADHD tool

• Has this product been tested in a published clinical trial? If so, was there a control group?
• Is it FDA-cleared or registered as a medical device, or is it a consumer wellness product?
• What data does the app collect, and how is it stored and used?
• Does the company distinguish between user engagement metrics and clinical outcomes?

If you are curious about where you stand, you can try our free online ADHD self-test to help organize your observations before a clinical conversation.

Who benefits most from digital therapeutics?

Digital therapeutics may be most useful for people who want to add a structured, non-medication component to their ADHD management, or for those who face barriers to accessing traditional in-person treatment. They are not a substitute for a thorough clinical evaluation or for established first-line treatments when those are appropriate.

Based on the current evidence, the people most likely to benefit include:

• Children aged 8 to 12 with confirmed ADHD who may be candidates for the FDA-cleared AKL-T01, used alongside (not instead of) other treatments.
• Adults looking for supplementary tools to support focus, organization, or habit-building, with realistic expectations about what consumer apps can and cannot do.
• People in areas with limited access to specialists who might use digital tools to bridge gaps between appointments.
• Individuals who prefer non-pharmacological approaches and want to explore options while understanding that the evidence base is still developing.

ADHD is a developmental disorder characterized by patterns of inattention, hyperactivity, or impulsivity that affect daily functioning across multiple settings (NIMH) [6]. Any digital tool should be evaluated in the context of a full treatment plan discussed with a clinician.

For a broader look at what is available beyond medication, see our guide to ADHD apps and tools.

What does the future look like for ADHD digital therapeutics?

The field is moving toward more rigorous testing, better regulatory clarity, and integration with clinical care rather than standalone use. Several trends are worth watching: larger randomized controlled trials for products currently supported only by pilot data, development of adaptive AI systems that personalize interventions in real time, and growing interest in combining digital tools with telehealth for ongoing monitoring.

A key challenge is standardizing how outcomes are measured. The 2025 umbrella review found that studies used widely different outcome measures, making it difficult to compare results across interventions or draw firm conclusions about which approaches work best (Gabarron et al., 2025) [2]. Until the field settles on consistent endpoints, it will be hard to build the kind of evidence base that leads to strong clinical recommendations.

Checklist: evaluating an ADHD digital therapeutic

Use this before downloading, purchasing, or committing time to any digital ADHD product:

• Is it FDA-cleared, in clinical trials, or a consumer product with no regulatory review?
• Has it been tested in a published randomized controlled trial with a control group?
• Were outcomes measured by blinded assessors, or only by self-report?
• Is the product designed for your age group (many are tested only in children)?
• What does it cost, and is any of that covered by insurance?
• Does it require a prescription or clinician involvement?
• What data does it collect, and what is the privacy policy?
• Does the company make claims that go beyond what their published data supports?

If you cannot answer most of these questions from the product's website, that itself is useful information.

Infographic: key points about adhd digital therapeutics. Regulatory status and published evidence vary widely across the digital therapeutics landscape.

Frequently asked questions

What is the difference between a digital therapeutic and a health app?

A digital therapeutic is a software-based treatment designed to treat or manage a specific medical condition, typically backed by clinical trial evidence and sometimes requiring a prescription. A health app might help with general wellness, reminders, or habit tracking without making treatment claims. The regulatory and evidence standards are different: DTx undergo clinical testing, while most health apps do not.

Is EndeavorRx available for adults?

EndeavorRx (AKL-T01) is currently FDA-cleared only for children aged 8 to 12 with ADHD. Single-arm trials in adolescents and adults showed improvements in attention measures, but these did not include a control group (Stamatis et al., 2024). An adult clearance would require additional evidence. Ask your clinician about the current status if you are interested.

Does neurofeedback cure ADHD?

No. Neurofeedback does not cure ADHD. Some studies suggest it may improve certain symptoms like inattention, but results are inconsistent across trials, and most clinical guidelines do not recommend it as a standalone treatment. It is sometimes used as a supplement to other approaches.

Are ADHD apps covered by insurance?

Most consumer ADHD apps are not covered by insurance because they are not classified as medical devices. FDA-cleared digital therapeutics like EndeavorRx may have some insurance coverage, but this varies by plan and region. Check with your insurer and the product manufacturer for current coverage details.

Can digital therapeutics replace ADHD medication?

Current evidence does not support using digital therapeutics as a replacement for medication in people who benefit from pharmacological treatment. A 2024 meta-analysis found that medication was more effective than game-based DTx for inattention and hyperactivity/impulsivity (Oh et al., 2024). Digital tools may complement medication, but decisions about treatment changes should always involve a clinician.

Are there risks or side effects from ADHD digital therapeutics?

Reported adverse effects have generally been mild, including physical discomfort (headaches, eye strain), emotional reactions, and in some cases behavioral issues like increased screen time. The 2025 umbrella review noted that adverse effects were inconsistently documented across studies, making it difficult to draw firm safety conclusions (Gabarron et al., 2025).

How do I know if an ADHD app is legitimate?

Look for published clinical trial data (not just testimonials), check whether the product has FDA clearance or is registered as a medical device, and review the privacy policy. Products that make strong treatment claims without citing specific studies should be approached with caution. The evaluation checklist in this article can help you assess any product systematically.

What is the role of virtual reality in ADHD treatment?

Virtual reality (VR) is being explored as both an assessment and intervention tool for ADHD. Some research groups are testing VR environments that simulate real-world distractions to measure attention. Evidence is still at the pilot-study stage, and no VR-based ADHD treatment has received FDA clearance. This is an area to watch, but not one with actionable clinical evidence yet.

Should I try a digital therapeutic before getting an ADHD diagnosis?

A thorough clinical evaluation should come first. Digital therapeutics are designed to be part of a treatment plan for a confirmed condition, not a substitute for diagnosis. If you suspect you may have ADHD, starting with a screening tool and then speaking with a clinician is a more reliable path than self-treating with an unvalidated app.

How long do you need to use a digital therapeutic to see results?

This varies by product. In the AKL-T01 adult trial, participants used the intervention for six weeks before outcomes were measured (Stamatis et al., 2024). Neurofeedback protocols typically run 20 to 40 sessions over several months. Consumer apps with no clinical data cannot provide evidence-based timelines. Ask the product manufacturer or your clinician for guidance specific to the tool you are considering.